NDUFB3

NDUFB3 is a structural subunit of mitochondrial respiratory Complex I whose presence is required for proper assembly and catalytic activity of the complex (PMID:22277967, PMID:22499348). Complementation of patient-derived mutant cells with wild-type NDUFB3 cDNA restores both Complex I activity and assembly, and a recurrent homozygous p.Trp22Arg variant produces a Complex I assembly defect detectable in patient skeletal muscle, establishing NDUFB3 loss-of-function as a cause of mitochondrial Complex I deficiency (PMID:22277967, PMID:22499348, PMID:27091925). NDUFB3 is post-translationally modified by the methyltransferase METTL9, which catalyzes 1-methylhistidine modification at an HxH motif; this methylation enhances Complex I-dependent respiration (PMID:33563959). Modulating NDUFB3 levels in cancer cell lines tunes Complex I activity, oxygen consumption, and mitochondrial ROS output, with overexpression elevating mitochondrial ROS and engaging downstream JNK signaling, cell-cycle arrest, and apoptosis (PMID:38437062, PMID:35087620).

1. 2009 Low

   An early question was whether NDUFB3 might be a methylation target during Complex I assembly; analysis of the assembly factor C20orf7 raised this possibility while directly confirming only that its loss impairs Complex I maturation.

   Evidence Blue Native gel electrophoresis of patient cells and domain analysis of C20orf7

   PMID:19542079

   Open questions at the time

   • Methylation of NDUFB3 by C20orf7 was inferred from a SAM-dependent domain, not directly demonstrated
   • No mapping of any modified residue on NDUFB3
   • Causal role of NDUFB3 itself not addressed
2. 2012 High

   Establishing NDUFB3 as a genuine structural subunit required showing that restoring it rescues the complex; wild-type cDNA complementation of patient mutant cells recovered Complex I activity and assembly, defining NDUFB3 as essential for Complex I biogenesis and a cause of mitochondrial disease.

   Evidence Functional complementation by wild-type cDNA transfection, Complex I activity assay, and Blue Native PAGE in patient cell lines (two independent studies)

   PMID:22277967 PMID:22499348

   Open questions at the time

   • Structural position of NDUFB3 within the assembled complex not resolved here
   • Mechanism by which specific mutations destabilize assembly not defined
3. 2016 Medium

   To consolidate the disease link, a recurrent variant was examined in patient tissue; the homozygous p.Trp22Arg substitution was shown to impair Complex I assembly in skeletal muscle, identifying a specific recurrent pathogenic allele.

   Evidence Blue Native PAGE on patient skeletal muscle plus targeted/whole-exome sequencing

   PMID:27091925

   Open questions at the time

   • Single-lab assembly analysis
   • Molecular basis of how Trp22Arg disrupts subunit incorporation not determined
4. 2021 High

   The long-standing question of whether NDUFB3 is methylated was answered by identifying its modifying enzyme: METTL9 installs a 1-methylhistidine mark at an HxH motif, and this modification enhances Complex I-dependent respiration, linking a post-translational mark to respiratory output.

   Evidence In vitro methyltransferase assay, MS site identification, METTL9 knockout mouse proteomics, and respiration assay

   PMID:33563959

   Open questions at the time

   • Effect of losing the methyl mark on Complex I assembly versus activity not separated
   • Structural consequence of histidine methylation on the subunit unresolved
5. 2022 Medium

   Whether NDUFB3 abundance actively tunes respiratory and redox output, beyond being permissive for assembly, was tested in thyroid cancer cells; gain and loss of NDUFB3 bidirectionally controlled oxygen consumption, ATP, Complex I activity, and mitochondrial ROS, with overexpression suppressing tumor growth in vivo.

   Evidence Overexpression/knockdown in cancer cell lines, OCR/ATP/Complex I/mitoROS assays, and xenograft model

   PMID:35087620

   Open questions at the time

   • Single-lab study
   • Whether effects are cancer-type specific not established
6. 2024 Medium

   A downstream signaling consequence of NDUFB3-driven ROS was placed mechanistically; in hepatocellular carcinoma cells, NDUFB3 overexpression raised Complex I activity and mitochondrial ROS, activated JNK signaling, and triggered G0/G1 arrest and apoptosis.

   Evidence shRNA knockdown/overexpression in HCC lines, Complex I activity and mitoROS assays, JNK western blot, flow cytometry, and xenograft model

   PMID:38437062

   Open questions at the time

   • Single-lab study
   • Direct link between NDUFB3-derived ROS and JNK activation not biochemically dissected

• How NDUFB3 is physically positioned within Complex I, and whether its METTL9-dependent methylation alters assembly versus catalysis, remains unresolved.
• No structural model of NDUFB3 within the assembled complex in the corpus
• Functional separation of methylation effects on assembly vs activity not established
• Mechanism connecting the subunit to redox-dependent JNK signaling not fully defined